PSA announces new Early Career Pharmacists directorship

The Pharmaceutical Society of Australia (PSA) welcomes the new Early Career Pharmacists (ECP) Board Director to the PSA National Board.

 

Today, 23rd August, Deanna Mill has been appointed as the Early Career Pharmacists Board Director, following the conclusion of Lauren Burton’s term.

 

Based in Adelaide, Ms Mill has acquired a unique breadth of skills and experience, having worked in rural, metropolitan, hospital, community, teaching and research settings. In addition to her comprehensive pharmacy experience, Ms Mill is also currently completing a Doctor of Philosophy (PhD) at the University of Western Australia.

 

PSA National President, A/Prof Chris Freeman, welcomed Ms Mill and thanked the outgoing Lauren Burton for her contribution to the role.

 

“Deanna’s achievements to date are very impressive, and we warmly welcome her to the PSA National Board.

 

“She is passionate about elevating ECP voices around the country and inspiring the broader profession to see beyond the current state of pharmacy practice, enabling innovation.

 

“Having worked in multiple practice settings and with her focus currently on researching the professional behaviour of pharmacists, she has unique insight into the disconnect between how pharmacists want to practice and what the current system allows.

 

“She will draw on her experiences to connect ECPs around the country, ensuring they have the support needed to build the future that they and all Australians want and deserve,” A/Prof Freeman said.

 

He went on to acknowledge Lauren Burton for her service to PSA and the profession at large.\

 

“On behalf of the PSA Board, I’d like to thank Lauren Burton for her contribution to the role over the past three years.

 

“ECPs make up a large proportion of PSA’s membership and are integral stakeholders in the Australian pharmacy sector – and Lauren has led this cohort by example.

 

“I would particularly like to acknowledge Lauren’s leadership in helping establish the Early Career Pharmacy Community of Specialty Interest. Her consultative and supportive approach to this work ultimately led to its launch at PSA21VIRTUAL.

 

“Lauren brought far more to the PSA Board in addition to her advocacy for ECPs. Lauren is a naturally gifted director with skills in governance and leadership – importantly bringing a ‘members first’ approach to considerations around the Board table. Lauren has a bright future ahead of her, and I am pleased she will continue in her role on the PSA WA Branch Committee,” A/Prof Freeman said.

 

PSA looks forward to Deanna’s directorship and warmly welcome her to the PSA National Board.

 

 

Media contact: PSA media 0424 777 463

PSA remembers the late Professor Andrew Gilbert AM

The Pharmaceutical Society of Australia (PSA) is saddened by the recent passing of one of Australia’s most influential pharmacists.

 

Last Friday, 20th August, Emeritus Professor Andrew Gilbert AM, peacefully passed away, surrounded by his family. He was appointed a Member of the Order of Australia for significant service to pharmacy as an educator, researcher, and administrator and to professional organisations.

 

Professor Gilbert, PSA Fellow and former Director of The Quality Use of Medicines and Pharmacy Research Centre, was internationally renowned for his research and consultancy work in areas of medicines policy and health practice change.

 

PSA National President, A/Prof Chris Freeman, was deeply saddened by the passing of his mentor and friend.

 

“The loss of Professor Gilbert, Andy, affects me deeply. He had such a big influence on my career. Andy was a mentor who took me under his wing, provided me with many opportunities, and offered a voice of reason when I felt uncertain. I know he played a similar role for many in the pharmacy profession. I am lucky to have called him a friend.

 

“Andy was instrumental in securing federal funding of Home Medication Reviews for at-risk people in the community, and further research on medication management issues in the veteran community.

 

“His research led to the publication and national adoption of the Professional Practice Standards with another program of research that enhanced outcomes for residents of aged-care facilities through improved medication use.

 

“In 2005, he was awarded the Pharmacist of the Year Award and the South Australian Pharmacist of the Year in 2004, for his work in medicines policy development, implementation and evaluation, pharmaco-epidemiology, and health practice change.

 

“Andy also contributed to the initiation of the ‘Veterans MATES’ program at the University of South Australia now led by Professor Libby Roughead. This unique program provides direct patient-based feedback to medical practitioners regarding medications provides to veterans.

 

“In recognition of his lifelong contribution to the pharmacy profession, PSA awarded Andy with Life Fellowship in 2019, at a ceremony in Adelaide attended by his family, friends and colleagues.

 

“PSA extends its condolences Andy’s wife Marg, his daughters Kate and Alice, and the rest of his family. His legacy and impact on pharmacy practice will not be forgotten,” A/Prof Freeman said.

 

<end>

 

 

Media contact: PSA media 0424 777 463

PSA welcomes Roadmap to improve the health of the intellectually disabled

The Pharmaceutical Society of Australia (PSA) supports the Government’s plan to improve the health of Australians living with intellectual disability.

 

Last Friday, 13th August, the Minister for Health and Aged Care, the Hon Greg Hunt MP, launched the National Roadmap for Improving the Health of People with Intellectual Disability.

 

This comprehensive plan will look to improve the health outcomes of people with intellectual disability in Australia over the next decade, with the Morrison Government initially committing $19.3 million to fund the first actions of the Roadmap.

 

The Roadmap will look to improve the overall standard of care and support that is provided to people with intellectual disability through more effective models of care, greater support for health workers, improved monitoring of their conditions and greater consideration in emergency planning and responses.

 

PSA National President, A/Prof Chris Freeman, expressed his support for the ten-year plan.

 

“PSA strongly supports the key objectives of the National Roadmap, in particular, the development of better models of care for people with intellectual disability and support for health professionals to deliver quality care for this cohort.

 

“While there is rightly an urgency to address inappropriate use of psychotropic medicines by people with intellectual disability, as PSA outlined in its submission to the Disability Royal Commission last year, there is broader concern for people with disability who require support with their medicines.

 

“It is vital that these vulnerable Australians, their families, and their carers have routine access to pharmacists and appropriate medication management programs to help ensure medication safety, support optimal and quality use of medicines and improve quality of life,” A/Prof Freeman said.

 

PSA SA/NT Branch Committee Member, Dr Manya Angley, who appeared as a witness at the Disability Royal Commission, highlighted various opportunities where pharmacists can identify inappropriate medicines use, and work with prescribers and other members of the disability care team to ensure quality use of medicines.

 

“People with intellectual disability experience stark mental and physical health disadvantage compared to the general Australian population.

 

“As medicines are the most powerful intervention used in health care, pharmacists are well positioned to improve overall health by ensuring quality use of medicines. Inappropriate medicine use, especially psychotropics, is a problem concerning both the health and disability sectors – hence, interdisciplinary collaboration is required to address it.

 

“My experience working in the sector is that it is equally challenging and rewarding. The key role pharmacists can play in the healthcare of these Australians needs to be clearly defined and resourced accordingly. The Roadmap is an opportunity to enable this,” Dr Angley said.

 

PSA looks forward to continuing the collaboration with all partners in implementing the initiatives of the comprehensive 10-year plan to improve the health outcomes of people with intellectual disability in Australia.

 

For further information on the Roadmap, please visit the National Roadmap for Improving the Health of People with Intellectual Disability | Australian Government Department of Health.

 

<end>

 

 

Media contact: PSA media 0424 777 463

Pharmacists quickly reach 100k rollout milestone

The Pharmaceutical Society of Australia (PSA) congratulates Australian pharmacists for standing up for their communities, as they pass an important milestone.

 

In a few short weeks, pharmacists have rapidly administered over 100,000 doses of the AstraZeneca vaccine, according to data from the Australian Immunisation Register (AIR).

 

PSA National President, A/Prof Chris Freeman, expressed his admiration of the pharmacy profession’s contribution to the rollout to date.

 

“Today’s data from the AIR is very pleasing, as more than 100,000 doses have been administered by pharmacists across our country.

 

“Considering that only a fraction of Australia’s pharmacists have commenced vaccinating in recent weeks, these numbers are quite staggering. Imagine the vaccination rates once all approved pharmacists are on-boarded.

 

“This data underpins the trust that Australians place in their local pharmacists to protect them against this deadly disease.

 

“I acknowledge the pharmacists who have been vaccinating through GP clinics, respiratory clinics, and vaccination hubs since day one of the vaccine rollout – they have paved the way for community pharmacist involvement in the strategy. I commend those pharmacies who have remained open beyond business hours and on weekends as they work toward safeguarding their communities.

 

“Vaccination by pharmacists is the patient-centric approach that Australians need and deserve – and this is the tip of the iceberg for the impact they can have on the vaccine rollout,” A/Prof Freeman said.

 

PSA looks forward to the arrival of the Moderna vaccine in mid-September and is dedicated to supporting pharmacists in delivering all COVID-19 vaccines both safely and effectively to the public.

 

<end>

 

 

Media contact: PSA media 0424 777 463

PSA welcomes new WA Branch President

The Pharmaceutical Society of Australia (PSA) WA Branch has elected a new president, following recent Branch elections.

 

Last week, the PSA WA Branch Committee elected Keegan Wong as the new Branch President, whilst outgoing President, Dr Fei Sim, has been appointed to the PSA National Board.

 

Since graduating from Curtin University in 2009, Mr Wong has become a successful practitioner and pharmacy owner. Mr Wong’s Priceline pharmacy in Kalamunda was awarded the WA Priceline Pharmacy of the Year 2019, and in that same year, he was named WA Priceline Pharmacist of the Year.

 

PSA Chief Executive Officer, Mark Kinsela, welcomed Mr Wong to the role and acknowledged the contribution of the outgoing Dr Fei Sim.

 

“Mr Wong’s service to the pharmacy profession to date is outstanding – and his experience and expertise will build on PSA’s existing momentum in WA.

 

“He has established health initiatives in his pharmacy, such as weight management clinics, sleep apnoea clinics, diabetes and sugar assessments and monthly blood pressure screenings.

 

“His community pharmacy management and proprietor skills have not only made him a leader in the industry, but have also allowed him to facilitate a contemporary, patient-centric practice environment,” Mr Kinsela said.

 

Mr Kinsela extended thanks to Dr Fei Sim for her exemplary contribution to the role and the profession as a whole.

 

“Over the past four years, PSA’s WA Branch has been led by one of the country’s most talented and well-respected pharmacists, Dr Fei Sim.

 

“Fei is a successful community pharmacy group owner and Fellow of the PSA. Fei is personable, accomplished and is the consummate professional.

 

“Dr Sim was the recipient of the JM O’Hara research grant from the Pharmaceutical Society of Australian (PSWA) in 2018. Through this grant, Dr Sim and her team conducted and published a feasibility study on Point-of-Care C-Reactive Protein Testing. It is hoped this project will contribute towards facilitating antimicrobial stewardship, and advancing evidence-based community pharmacy practice to improve recognition of pharmacists’ roles and remuneration.

 

“Fei has truly been an asset to WA pharmacists and we are delighted that she has been elevated to a Director on the PSA National Board – continuing to support the important work of the profession,” Mr Kinsela said.

 

PSA looks forward to Mr Wong’s leadership and welcomes him as the WA Branch President.

 

<end>

 

 

 

Media contact: PSA media 0424 777 463

Pharmacists to administer first doses of Moderna

Note: For further information on how to book your vaccine appointment, please visit the Department of Health website.

 

The Pharmaceutical Society of Australia (PSA) welcomes the Prime Minister’s announcement that pharmacists will be among the first to administer initial doses of the Moderna vaccine.

 

This afternoon, the Therapeutic Goods Administration (TGA) provisionally approved use of the Moderna vaccine, with the Morrison Government confirming that the first doses will be distributed to approved community pharmacies.

 

PSA National President, A/Prof Chris Freeman, welcomed this afternoon’s news and called for further improvements to vaccine access.

 

“PSA commends the Government’s announcement that pharmacists will be prioritised in the rollout of Moderna planned for September.

 

“Whilst this is welcomed news for Australians, it is important that governments continue to expand access to vaccines. This includes allowing pharmacists to administer all COVID19 vaccines where supply is available.

 

“In order to ensure we achieve high rates of vaccination and overcome vaccine hesitancy, we must utilise all pharmacists, all TGA-approved vaccines, and all practice settings.

 

“Pharmacists are one of our most accessible frontline health workforces and community pharmacies are open beyond business hours and on weekends. Pharmacists must play a key role for Australia to complete this vaccine rollout,” A/Prof Freeman concluded.

 

PSA is dedicated to supporting pharmacists in delivering all COVID-19 vaccines both safely and effectively to the public, and pharmacists remain committed to supporting the strategy wherever possible.

 

<end>

 

 

Media contact: PSA media 0424 777 463

 

PSA launches Residential Aged Care Pharmacist: Foundation Training Program

The Pharmaceutical Society of Australia (PSA) has launched a new training program to support pharmacists working in residential aged care, as a new emerging role.

 

PSA’s Residential Aged Care Pharmacist: Foundation Training Program is an accredited CPD activity that will help Australian pharmacists upskill for aged care practice settings.

 

The course will support recommendations from the Royal Commission into Aged Care Quality and Safety which focussed on ways to improve quality use of medicines and reduce the use of chemical restraints.

 

PSA National President, A/Prof Chris Freeman, shed light on the new course.

 

“I am delighted to announce the launch of PSA’s Aged Care Foundation Training Program. This project has been in development for some time and has been designed to support a critical area of pharmacist practice, as evidenced by the Royal Commission.

 

“PSA’s Medicine Safety: Take Care and Medicine Safety: Aged Care reports found that 98 percent of aged care residents have at least one medicine-related problem, and over half are exposed to at least one potentially inappropriate medicine.

 

“Pharmacists working in residential aged care facilities can help improve the quality use of medicines and health outcomes of aged care residents by using their clinical knowledge to its full extent, and limiting the incidence of harm from suboptimal or inappropriate use of medicines.

 

“The Aged Care Foundation Training Program is the only short CPD course available of its kind that specifically focuses on the needs of pharmacists, taking into account their background as medicines experts.

 

“Completion of this course will ensure that pharmacists are equipped with the knowledge, skills and confidence to work with the elderly, ensuring pharmacists can better contribute to quality use of medicines in residential aged care.

 

“We need all pharmacists to practise to full scope, and playing a more targeted role in residential aged care will be a significant step toward improving clinical practice, medication management and safety in this environment.

 

“Having more pharmacist time on-site in these facilities improves the standard of residents’ care and will prevent avoidable harm and death – providing reassurance to residents and their loved ones,” A/Prof Freeman said.

 

PSA believes that there is a need for strong clinical leadership in the pharmacy profession, to engage pharmacists in these important areas of practice and to demonstrate the value of enhanced medication management reviews.

 

For further information on the aged care pharmacy, please visit this link. For more information on the course itself, please click here.

 

<end>

 

 

Media contact: PSA media 0424 777 463

PSA21VIRTUAL: QUT take out PSOTY honours

Last night, The Pharmacy Student of the Year (PSOTY) awards were conducted at PSA21VIRTUAL, with Queensland University of Technology’s Zoe Robinson winning and claiming the honours. 

 

PSOTY awards recognise and celebrate outstanding pharmacy students by showcasing their counselling skills to the pharmacy profession and is a highlight of PSA’s annual flagship conference. 

 

PSA extends thanks to the PSOTY award sponsor, Viatris, for their ongoing support of the event, and looks forward to working with them again in 2022.

 

Congratulations also to Dharshan Rasiah from the University of South Australia, who took out the People’s Choice award. 

 

PSA National President, A/Prof Chris Freeman, congratulated Ms Robinson on her achievement and commended the talent of all finalists.

 

“It is heartening to see the future of our profession on show, demonstrating a high level of clinical knowledge, capability and passion – evidently, the future of pharmacy is incredibly bright.

 

“I congratulate Zoe on her achievement and would like to thank all the finalists in what was a difficult decision for the judging panel. 

 

“This competition provides students the opportunity to demonstrate important skills such as gaining patient insights and patient understanding, active listening and skills that support positive patient outcomes.

 

“We commend each finalist for the professionalism they displayed when communicating with the patient, taking patient history, excluding serious medical conditions and subsequently arriving at an appropriate clinical recommendation,” A/Prof Freeman concluded.

 

As winner of the national award, Ms Robinson has received a travel prize for pharmacy-specific education to the value of $5,000.

 

<end>

 

Media contact: PSA media 0424 777 463

Transcript: National President’s Address at PSA21VIRTUAL

Associate Professor Chris Freeman:

 

Good morning. Thank you all for joining us.

 

I would like to acknowledge the traditional custodians of the Turrbal and Yuggera peoples of the lands that I am speaking to you from today. I also acknowledge the traditional custodians of the lands on which each of you are living, learning and practising from today. As we share our knowledge and wisdom, may we also pay respect to our Elders, both past and present, as it is their knowledge and experiences that hold the key to the success of future generations.

 

I extend a warm welcome to everyone online today, joining us live across Australia. I particularly welcome you, our members; the pharmacists of Australia. An especially warm welcome to those pharmacists living and working from current lockdown areas – our thoughts are with you.

 

While all of you pivoted your practice during COVID-19, so has PSA, and I am thrilled to be speaking to you through this impressive digital platform to all corners of the country. For every Australian, the pandemic has been hard. Harder for some than others. But hard for everyone – including every one of you. I extend my sincere thanks to you – Australia’s pharmacists, from every walk of practice, and in every hospital and community, who have been on the frontline since day one of this global health crisis. Your patients needed you. You couldn’t stay home. You had to contend with public panic, anxiety, rapidly changing regulations, medicine shortages and workplace operations were turned upside-down. You also had to work with the fear of becoming sick. We know at least 63 pharmacists contracted COVID-19 in Victoria’s second wave. Many others were and continue to be intimately impacted, most recently in New South Wales. I commend and thank all frontline pharmacists for your hard work, dedication and professionalism under immense pressure. I also extend my sincere thanks to pharmacists in other practice environments – in government, defence, education and in professional bodies. You played a significant role in keeping Australians safe during the pandemic.

 

While it is often said the wheels of government turn slowly, this hasn’t been the case for pharmacists in supporting significant health and regulatory change. These changes are likely to be ongoing. Expanded PBS Continued Dispensing, telehealth, electronic prescriptions have all been accelerated by the bushfire and pandemic crises. PSA will not give up on good policy recommendations such as the proper implementation and expansion of therapeutic substitution, as now it remains an example of bureaucratic red tape that stifles pharmacists helping patients in need. Because of how you stood up, it is becoming easier for PSA to campaign for change. Change which supports your patients, change which supports the community, and change which recognises you and your contribution. A focus for us now is to improve vaccination remuneration for pharmacists.

 

Our colleagues in the UK receive the equivalent of 30 Australian dollars per vaccination, not dissimilar to the funding received by Australian GP’s. It is nearly double the current private market or payment for COVID-19 vaccination by pharmacists in Australia. No matter your practice environment, we will fight for fairer recognition. Vaccination has been the political football of 2021. Polarising media coverage, shifting clinical guidance and political barbs have become our daily norm. However, while others argued, pharmacists got organised. You got ready. Over 2,000 of you have undergone vaccination training in the past 12 months. This surge now means over 50 percent of all pharmacists in Australia are now trained vaccinators. Over 3,900 community pharmacies submitted their EOI’s, showing they were ready and deemed eligible. You got started. Frustratingly, while the community pharmacies sat waiting on the bench, pharmacists in hospitals, vaccination hubs, general practice and ACCHO’s started vaccinating. Some pharmacists went into quarantine hotels to administer Australia’s first vaccines in red zones. Others joined the aged care vaccine workforce.

 

I am so excited that, finally, all pharmacist vaccinators are being brought on board over the next few weeks with the activation of community pharmacies through August. Long overdue, this will accelerate Australia’s exit from the pandemic. But this hasn’t come easy. Your PSA has had to fight hard for this. We fought for every one of the individual changes to state and territory regulations during the past 6 months. Changes that removed unfair restrictions stopping pharmacists fully playing our part protecting the community. We fought hard for the activation of community pharmacists in the media and behind closed doors. We continue to look for wins on your behalf – particularly in ending mRNA vaccine discrimination and fair remuneration.

 

On that topic, a little bit like house prices, the supply and demand equilibrium for pharmacists has changed. Increased demand for pharmacists during the pandemic, including in supporting the COVID-19 vaccine roll-out, has seen upward pressure on wages. As one of the profession’s primary concerns, this increase in remuneration is welcome. However, outside the supply and demand swings of the pandemic, meaningful increases in wages is going to require more high value roles for pharmacists outside the “four walls” of a community pharmacy, and more money within the community pharmacy sector. Pushing towards ‘full-scope-of-practice’ for pharmacists achieves both of these. Released in February 2019, Pharmacists in 2023 is the profession’s blueprint for full scope of practice in all settings where pharmacists work. We are committed to making it happen. We already have runs on the board.

 

PSA’s leadership in advocating for and supporting you in administration of medicines by injection and vaccination has created real opportunities to charge for high-value services – which during the conference, Dr Shane Jackson, talks more about on Sunday afternoon. PSA’s leadership in creating your future roles also has the profession well on the path to full scope of practice. Roles in general practice, palliative care, aged-care and Aboriginal Community Control Health Organisations. You’ll hear more on this in the aged-care session later this afternoon and the Close the Gap session on Sunday. Through PSA-led projects, over 60 of you have practised in in these emerging roles, creating the evidence for future expansion across Australia. Pharmacists like Ellen Jones in a North Queensland ACCHO, Julian Soriano in South Australia’s palliative and aged care, and Mayli Foong as a Western Australian general practice pharmacist. We are now seeing governments and private providers committing resources to these roles knowing they work. Julian and Mayli will talk about their work throughout the conference.

 

We know, pharmacists are the medicine experts. That’s why we know how important medicine safety is. As Australia embarks on a review of the National Medicines Policy, we will continue to set the agenda, around medicines safety and Quality Use of Medicines, building on the significant work PSA has led through our Medicine Safety series. I have spoken with the Minister for Health, the Honourable Greg Hunt, in the last 24 hours, and he has asked me to make an important announcement regarding the National Medicines Policy Review. Earlier this year, the Minister announced that Professor Michael Kidd will Chair the expert advisory committee to lead the review of the National Medicines Policy. Today I am pleased to announce, on behalf of the Minister, the rest of the National Medicines Policy Committee, including PSA Life Fellow Professor Lloyd Sansom; Janette Donovan; PSA Branch Committee member Dr Sarah Dineen-Griffin, and David Herd. This Committee brings expertise in medicines policy, clinical practice, consumer engagement and the pharmaceutical industry to the Review. The Committee will report to the Minister for Health through the Chair. The Minister will also release the terms of reference for the review this morning. The review process will begin in August 2021 and is anticipated to take approximately six months. PSA looks forward to working closely with the Committee to ensure medicines safety and quality use of medicines are strengthened as a central pillar of the National Medicines Policy.

 

Just as you have stood up, so has PSA, your professional organisation. Last year, we focussed on helping you navigate the pandemic. We established a microsite to help comprehend all the regulatory changes and practice issues as they arose. This microsite had over 170,000 views and became a go-to resource not just for pharmacists, but also for government departments and doctors trying to navigate their legal obligations. We continue to maintain the page, updated now to include state-by-state comparisons of vaccine regulations and access. Despite diverting resources to supporting you during the pandemic, we continued to deliver for you in education, advocacy and support. We established the pharmacist-to-pharmacist support line, which has already taken nearly 3,000 calls from members. Your PSA kept producing new CPD content for you, on the full breadth of clinical topics and practice issues. And despite the demands of serving your patients in the pandemic, you collectively worked through 200,000 education activities offered through 2020. And your PSA was first in bringing back face-to-face learning in the Annual Therapeutic Updates across 2021. After a period of stability, it is indeed cruel that pharmacists in our host city of PSA21 are facing such a challenging outbreak at this time. Again, all of our thoughts are with you. Please reach out to your PSA for any support your need.

 

On the topic of delivering for members, I am pleased to announce a new member benefit; the Communities of Special Interest. For a long time, you have been asking for ways to come together and support innovation and strategic progression in specific areas of clinical practice. The Communities of Specialty Interest (CSI’s) are a new way for members to engage and set the future of the profession and PSAs work. PSA members can join a CSI and will benefit from the strategic advice, support and dedication of its leadership and practice groups. The first of these will be the Early Career Pharmacists CSI. I encourage all PSA ECPs to visit PSA’s website to join. PSA will announce and launch three additional CSI’s in September, which will be led by Dr Fei Sim, Debbie Rigby and Sinthia Bosnic-Anticevich.

 

It remains important that we continue to recognise pharmacists who have gone above and beyond and this year we will recognise the PSA Excellence Award winners on World Pharmacist Day 25th September.

 

Finally, none of this will be possible without you – our members. I say to you, the strength of PSA, is you, our members. If you are not a member, I strongly encourage you to sign up. We need you to stand behind the Society in achieving the outcomes we all want, and our patients need. One thing I can tell you is that we won’t waiver from the objectives.

 

With that, I invite the Honourable Greg Hunt, Minister for Health and Aged Care, to say a few words.

 

Thank you.

 

<end>

 

 

Media contact: PSA media 0424 777 463

PSA21VIRTUAL: PSA announces Communities of Specialty Interest

The Pharmaceutical Society of Australia (PSA) is delighted to launch the Early Career Pharmacists Communities of Specialty Interest (CSI) group, during this morning’s session at PSA21VIRTUAL.

 

The CSI-ECP is the first of a number of CSI’s that PSA will be releasing over the next few months. The CSI’s will be the facilitated online forum for developing focused strategy, policy, and practice training and tools, which will propel the profession into the future.

 

The CSI’s have been established in order to deliver an exclusive member benefit and demonstrates that PSA is committed to professional development and industry growth. These forums will allow members to collaborate, network and voice opinions that will shape the profession.

 

The Early Career Pharmacists CSI group will build on the strong platform of the ECP working groups, and will continue to provide leadership from early career pharmacists to PSA. The CSI-ECP seeks to identify areas of importance to early career pharmacists and to propose solutions, provide data, develop insights and assist with testing ideas that address current strategic gaps.

 

PSA National President, A/Prof Chris Freeman, explained how the forums will benefit the profession as a whole.

 

“We are delighted to launch these innovative forums and are confident that they will have a positive impact on the pharmacy profession in Australia.

 

“The CSI’s will provide members with an opportunity to discuss current and emerging practice needs and speciality interests, through dedicated leadership and group forums.

 

“The principle focus of the CSI’s is to provide a pharmacist’s perspective in a defined practice area, and to support the vision and mission of the PSA relating to that practice.

 

“PSA is constantly encouraging members to translate their passion, and these forums will prompt them to shape new policies, models of practice, strategic guidelines, career pathways and practice tools,” A/Prof Freeman said.

 

In September, PSA will launch three new CSI’s in the areas of Contemporary Community Pharmacy Practice, Interdisciplinary Team-based Care, and Respiratory Care.

 

For more information on PSA CSI’s, please visit psa.org.au/csi.

 

<end>

 

 

Media contact: PSA media 0424 777 463